免疫检查点抑制剂治疗后的甲状腺免疫相关不良事件
该回顾性队列研究纳入1246例接受CTLA-4和/或PD-1抑制剂治疗的黑色素瘤患者,中位随访11.3个月,42%发生甲状腺免疫相关不良事件,亚临床甲状腺毒症最常见;联合免疫治疗、女性、年轻与甲状腺毒症发生相关,基线TSH升高和女性与甲状腺功能减退相关。
要点
- 甲状腺irAE发生率42%,亚临床甲状腺毒症最常见,其次为明显甲状腺毒症、亚临床甲减和明显甲减。
- 联合免疫治疗与明显甲状腺毒症强烈相关(OR 10.8),女性及年轻也为危险因素。
- 明显甲状腺毒症与更长PFS和OS相关,甲减与肿瘤结局无关。
核心结论
- 甲状腺irAE常见且存在多种不同表型,不同亚型具有独特的临床和生化关联。
研究设计与样本
- 回顾性队列研究,纳入2009年11月1日至2019年12月31日接受CTLA-4和/或PD-1抑制剂治疗的黑色素瘤患者1246例,中位随访11.3个月。
主要发现
- 明显甲状腺毒症中位发生时间为首次ICI给药后5周(IQR 2-8),明显甲减中位发生时间为14周(IQR 8-25)。
- 联合免疫治疗与明显甲状腺毒症强烈相关(OR 10.8,95%CI 4.51-25.6,对比CTLA-4单药,P<.001),女性(OR 2.02,95%CI 1.37-2.95,P<.001)和年轻(每10年OR 0.83,95%CI 0.72-0.95,P=.007)亦相关。
- 甲减最强关联因素为基线TSH较高(每mIU/L OR 2.33,95%CI 1.61-3.33,P<.001)和女性(OR 3.31,95%CI 1.67-6.56,P=.01),明显甲减频率在不同ICI类型间无差异。
- 明显甲状腺毒症与更长无进展生存(HR 0.68,95%CI 0.49-0.94,P=.02)和总生存(HR 0.57,95%CI 0.39-0.84,P=.005)相关,甲减与肿瘤结局无关联。
临床怎么用
- 接受ICI治疗的患者应基线和定期监测甲状腺功能,尤其联合免疫治疗、女性和年轻患者。
- 甲状腺毒症多在ICI开始后5周左右出现,甲减多在14周左右出现,监测时机可参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical presentation can be variable. OBJECTIVE: This study sought to define thyroid irAEs following immune checkpoint inhibitor (ICI) treatment and describe their clinical and biochemical associations. METHODS: We performed a retrospective cohort study of thyroid dysfunction in patients with melanoma undergoing cytotoxic T-lymphocyte antigen-4 (CTLA-4) and/or programmed cell death protein-1 (PD-1) based ICI treatment from November 1, 2009, to December 31, 2019. Thyroid function was measured at baseline and at regular intervals following the start of ICI treatment. Clinical and biochemical features were evaluated for associations with ICI-associated thyroid irAEs. The prevalence of thyroid autoantibodies and the effect of thyroid irAEs on survival were analyzed. RESULTS: A total of 1246 patients were included with a median follow-up of 11.3 months. Five hundred and eighteen (42%) patients developed an ICI-associated thyroid irAE. Subclinical thyrotoxicosis (n = 234) was the most common thyroid irAE, followed by overt thyrotoxicosis (n = 154), subclinical hypothyroidism (n = 61), and overt hypothyroidism (n = 39). Onset of overt thyrotoxicosis occurred a median of 5 weeks (interquartile range [IQR] 2-8) after receipt of a first dose of ICI. Combination immunotherapy was strongly associated with development of overt thyrotoxicosis (odds ratio [OR] 10.8, 95% CI 4.51-25.6 vs CTLA-4 monotherapy; P < .001), as was female sex (OR 2.02, 95% CI 1.37-2.95; P < .001) and younger age (OR 0.83 per 10 years, 95% CI 0.72-0.95; P = .007). By comparison, median onset of overt hypothyroidism was 14 weeks (IQR 8-25). The frequency of overt hypothyroidism did not differ between different ICI types. The strongest associations for hypothyroidism were higher baseline thyroid-stimulating hormone (OR 2.33 per mIU/L, 95% CI 1.61-3.33; P < .001) and female sex (OR 3.31, 95% CI 1.67-6.56; P = .01). Overt thyrotoxicosis was associated with longer progression free survival (hazard ratio [HR] 0.68, 95% CI 0.49-0.94; P = .02) and overall survival (HR 0.57, 95% CI 0.39-0.84; P = .005). There was no association between hypothyroidism and cancer outcomes. CONCLUSION: Thyroid irAEs are common and there are multiple distinct phenotypes. Different thyroid irAE subtypes have unique clinical and biochemical associations, suggesting potentially distinct etiologies for thyrotoxicosis and hypothyroidism arising in this context.
引用
- Muir CA, Clifton-Bligh RJ, Long GV, et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. J Clin Endocrinol Metab. 2021. PMID: 33878162. doi:10.1210/clinem/dgab263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。